Depression and Anxiety Trial, Recruiting NCT06927076 Sponsor: University Hospital, Basel, Switzerland Condition: Depression and Anxiety
Back to Depression And Anxiety

Depression and Anxiety Trial, Recruiting

NCT06927076
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with moderate or severe depression (based on a standard medical assessment)
  • You either do not currently take antidepressants, or you have been on a stable antidepressant dose for at least 4 weeks before joining
  • You are 21 years old or older
  • You have a good enough understanding of the German language to participate
  • You are able to understand what the study involves and are willing to follow the study rules and sign a consent form
  • You are willing not to drive or operate heavy machinery on the day you receive the treatment
  • You are willing to limit alcohol to no more than 7 drinks per week, cigarettes to no more than 10 per day, coffee to no more than 2 cups per day, and to avoid illegal substances during the study
  • You are willing to use effective birth control throughout the study

Who may not be able to join:

  • You have ever had, or currently have, bipolar disorder or a psychotic disorder, including depression with psychotic features
  • A close blood relative (parent, sibling, or child) has been diagnosed with a psychotic or bipolar disorder
  • You show significant early warning signs of psychosis (confirm with trial site)
  • You have a psychiatric condition that could make it unsafe or difficult to work with the study team, such as borderline personality disorder
  • You currently have post-traumatic stress disorder (PTSD) or are experiencing acute stress from a recent traumatic event
  • You are experiencing post-partum depression (depression after giving birth)
  • You are currently pregnant or breastfeeding
  • You have had serious thoughts of suicide or suicidal behaviour in the past 6 months
  • You currently have a severe substance use disorder (other than nicotine/tobacco)
  • You have had, or are planning, treatment with ketamine, other psychedelics, or electroconvulsive therapy (ECT) within the past 3 months
  • You have ever used DMT before, used any other psychedelic substance in the past 3 months, or have used any psychedelic substance more than 15 times in your life
  • You are taking certain medications — including antipsychotics, specific serotonin-blocking drugs, or MAOIs — and are unable or unwilling to pause them (confirm with trial site)
  • You have a known or increased risk of a bad reaction to propofol (an anaesthetic) or soy products
  • You have an increased risk of inhaling fluid into your lungs during a procedure (confirm with trial site)
  • You have features that could make it difficult to safely manage your breathing during the procedure (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 30 June 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University Hospital, Basel, Switzerland
Registry
ClinicalTrials.gov
Start date
5 August 2025
Est. completion
1 March 2029

Where this trial is recruiting

🇨🇭 Switzerland

Primary endpoints

long term changes in depressive symptoms (MADRS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov